Brainstorm Cell Therapeutics In (BCLI) Financials
BCLI Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 5.7 million | 8.3 million |
2023-06-30 | 5.7 million | 9.6 million |
2023-03-31 | 7.9 million | 12.7 million |
2022-12-31 | 8.5 million | 11.5 million |
BCLI Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -6.4 million | 548000 |
2023-06-30 | -6.8 million | 988000 |
2023-03-31 | -4.0 million | 4000 |
2022-12-31 | -4.6 million | 377000 |
BCLI Net Income
No data available :(
BCLI Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 1.4 million | - | 2.9 million |
2023-06-30 | 748000 | - | 3.3 million |
2023-03-31 | 2.2 million | - | 3.7 million |
2022-12-31 | 3.0 million | - | 4.1 million |
BCLI Shares Outstanding
BCLI Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 18000 | 3.3 million | 2.7 million | - |
2023-06-30 | - | 2.8 million | 2.7 million | - |
2023-03-31 | - | 2.9 million | 2.2 million | - |
2022-12-31 | 29000 | 2.5 million | 2.5 million | - |
BCLI Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | 65000 |
2023-06-30 | 154000 | 67000 |
2023-03-31 | -497000 | 497000 |
2022-12-31 | - | 70000 |
BCLI
Price: $0.38
52 week price:
Earnings Per Share: -0.42 USD
P/E Ratio: -0.92
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 566900
Ebitda: -2.4 millionMarket Capitalization: 28.3 million